Advertisement

Organisation › Details
Evotec (Group)
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. *
![]() |
Start | 2001-10-02 existent |
![]() |
Industry | drug discovery technology |
Industry 2 | drug discovery services | |
![]() |
Person | Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey) |
Person 2 | Spillner, Enno (Evotec 201607– CFO before 4SC CEO + CFO before BioM Venture Capital GmbH) | |
![]() |
Region | Hamburg |
Country | Germany | |
Street | 7 Essener Bogen Manfred Eigen Campus | |
City | 22419 Hamburg | |
Tel | +49-40-56081-0 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | F: 1,001 to 5,000 (2021-12-31) |
Currency | EUR | |
Annual sales | 618,034,000 (revenues, consolidated (2021) 2021-12-31) | |
Profit | 215,510,000 (2021-12-31) | |
Cash | 699,326,000 (2021-12-31) | |
* Document for �About Section�: Evotec AG. (5/31/18). "Press Release: Evotec Forms Academic Bridge »LAB591« with Arix Bioscience and Fred Hutchinson Cancer Research Center". Hamburg. | ||
Record changed: 2022-05-17 |
Advertisement

More documents for Evotec (Group)
- [1] Sernova Corporation. (1/10/23). "Press Release: Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes". London, ON....
- [2] Evotec SE. (10/28/22). "Press Release: Evotec, CDP Venture Capital and Angelini Ventures Launch Translational Partnership »Extend« with Leading Italian Academic Institutions". Hamburg....
- [3] Evotec SE. (10/25/22). "Press Release: Evotec Enters Partnership with Hannover Medical School to Create Molecular Patient Database in Autoimmune Diseases". Hamburg....
- [4] Adapsyn Bioscience Inc.. (9/21/22). "Press Release: Adapsyn Bioscience Enters into Strategic Collaboration with Evotec". Hamilton, ON....
- [5] Evotec SE. (9/20/22). "Press Release: Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense under Accelerated Antibodies Program". Hamburg....
- [6] Evotec SE. (9/16/22). "Press Release: Evotec Initiates Ground-breaking for New Biologics Facility J.POD Toulouse, France (EU)". Hamburg....
- [7] Evotec SE. (8/25/22). "Press Release: Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany". Hamburg....
- [8] Evotec SE. (7/6/22). "Press Release: Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance". Germany & France....
- [9] Evotec SE. (7/5/22). "Press Release: Evotec Completes Acquisition of Rigenerand". Hamburg....
- [10] Evotec SE. (6/14/22). "Press Release: Evotec Enters a Drug Discovery Collaboration with Janssen". Hamburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top